III only C
Previous studies have suggested that deficiency in GLP-1 secretion partly contribute to the diminished incretin effect typically observed among Caucasians with T2D ( 2 Materials and methods 2.1 Study participants This was a prospective study conducted over a 12-week period
GIP Medications: Whats the Difference
Direct-to-Consumer (DTC) Weight-Loss Medication Market Size, Share & Trends Analysis Report By Drug Type (Prescription Medications, OTC Medications, Herbal and Natural Supplements), By Route of Administration (Oral, Injectable, Others), By Distribution Channel (Online Pharmacies, Drug Stores & Retail Pharmacies, Direct Brand websites) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034 Last Updated: July 24, 2026 | Author: Debashree B | Format: | Report Code: SR7264DR | Pages: 110 Direct-to-Consumer (DTC) Weight-Loss Medication Market Size & Growth Analysis The global direct-to-consumer (DTC) weight-loss medication market size is valued at USD 8.64 billion in 2025 and is estimated to reach USD 35.61 billion by 2034, growing at a CAGR of 17.08% during the forecast period
